MIRXES-B (02629) announced that the company has entered into a strategic partnership with N Health (a healthcare solutions provider and a member of Bangkok Dusit Medical Services (BDMS) Group, Thailand's largest healthcare provider) on December 15, 2025. This strategic partnership aims to introduce advanced microRNA (miRNA) cancer screening solutions into Thailand, marking a significant step forward for the country and the broader region in enhancing early cancer detection and improving patient outcomes. The partnership enters Thailand's health check-up market, which is currently experiencing substantial growth. By 2030, Thailand's health check-up market size is projected to reach approximately $500 million, with a compound annual growth rate of 9.2% starting from 2025; its specialized health check-up segment is the fastest-growing, indicating strong demand for advanced and targeted screening solutions. This robust market, coupled with increasing awareness of preventive healthcare and a rising prevalence of chronic diseases, creates an ideal environment for adopting innovative diagnostic technologies, such as the company's miRNA tests. Driven by a shared commitment to healthcare advancements, the partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer. Through this strategic partnership, the company's cancer screening tests will be introduced into nearly 60 hospitals within the N Health network, utilizing a scalable model to support the broader provision of early disease detection services in Thailand and Southeast Asia, thereby helping to improve the region's standards of cancer care. N Health aims to strengthen its role in providing end-to-end healthcare solutions, while the partnership will also enable N Health to integrate advanced cancer risk assessment into preventive care, supporting early intervention and promoting healthier aging as Thailand transitions into an aging society. Furthermore, the strategic partnership is set to transform how cancer is identified and managed in Thailand, while paving the way for the company's growth across Southeast Asia. The Board further announced that, following approvals granted by the Thai FDA in October 2025 and December 2025 respectively, the company launched a new series of at-home screening test kits in Thailand on January 9, 2026: HELICORapid (designed to detect Helicobacter pylori (H. pylori) infection, a known primary and significant cause of gastric cancer) and FITRapid (designed to detect fecal occult blood, an indicator of colorectal cancer or polyps). These two direct-to-consumer cancer risk factor tests are designed to complement and synergize with the company's core innovative miRNA cancer screening solutions (including the Thai FDA-approved GASTROClear™ and its pipeline of colorectal cancer and multi-cancer blood tests), enabling the company to extend its sales and marketing efforts into the consumer domain. The new test kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into one compact unit. This proprietary design, protected by registered intellectual property, minimizes handling steps and significantly reduces the risk of contamination and user error, representing a particularly important improvement when handling stool-based samples. By offering simple-to-use, hygienic, and reliable at-home tests through modern trade and pharmacy channels, the company makes preventive healthcare more accessible to a wider population without sacrificing scientific rigor or user safety. Fecal occult blood testing is widely used as a frontline screening method for colorectal abnormalities, while H. pylori infection is an established risk factor for gastric diseases, particularly gastric cancer. Both indicators are also closely linked to gastrointestinal diseases and are recognized as crucial markers for the early detection of gastric and colorectal cancers. These at-home test kits enable patients to detect cancer early and encourage timely medical consultation, serving as important first-line screening tools that complement the company's broader early cancer detection ecosystem, which includes advanced molecular diagnostics. To ensure widespread accessibility, the company will distribute these test kits through modern trade channels and pharmacy networks across Thailand, aligning with evolving consumer healthcare behaviors and the growing demand for preventive, self-administered diagnostics. The product launch underscores the company's mission to democratize early detection, empowering individuals with practical tools to take control of their health while supporting healthcare systems through early intervention and increased disease awareness. This also represents a significant milestone in the company's long-term strategy to expand early cancer detection beyond hospitals and laboratories, making reliable screening solutions applicable in everyday consumer settings.
Comments